K36 Therapeutics Releases Groundbreaking Clinical Data on Gintemetostat and Appoints New Chief Medical Officer K36 Therapeutics has unveiled promising first-in-human clinical data for Gintemetostat in multiple myeloma and announced Dr. Shinta Cheng as CMO.

K36 Therapeutics Releases Groundbreaking Clinical Data on Gintemetostat and Appoints New Chief Medical Officer #USA #Orlando #K36_Therapeutics #Multiple_Myeloma #Gintemetostat